Adjuvant chemotherapy for non-small cell lung cancer: Practice patterns and outcomes in the general population of Ontario, Canada

Journal of Thoracic Oncology

Volumn 7, Issue 3, 2012, Pages 559-566

  Booth, Christopher M ^a,b   Shepherd, Frances A ^c   Peng, Yingwei ^a   Darling, Gail ^d   Li, Gavin ^a,b   Kong, Weidong ^a,b   Mackillop, William J ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Chemotherapy; Comparative effectiveness; Lung cancer; Outcomes research; Practice patterns

Indexed keywords

CARBOPLATIN; CISPLATIN; NAVELBINE;

ADULT; AGED; ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; FEMALE; HOSPITALIZATION; HUMAN; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEGMENTECTOMY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84862823175     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31823f43af     Document Type: Article

References (18)

1. Booth CM, Shepherd FA. Adjuvant chemotherapy for resected nonsmall cell lung cancer. J Thorac Oncol 2006;1:180-187. (Pubitemid 47189141)
2. Booth CM, Shepherd FA, Peng Y, et al. Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. J Clin Oncol 2010;28:3472-3478.
3. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597. (Pubitemid 41007845)
4. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727. (Pubitemid 44283661)
5. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559.
6. Douillard JY, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol 2010;5:220-228.
7. Alam N, Shepherd FA, Winton T, et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer 2005;47:385-394. (Pubitemid 40248743)
8. Robles SC, Marrett LD, Clarke EA, et al. An application of capturerecapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol 1988;41:495-501.
9. Clarke EA, Marrett LD, Krieger N. Cancer registration in Ontario: a computer approach. In Jenson OM, Parkin DM, MacLennan R. (Eds.), Cancer Registration Principles and Methods. Lyon, France: IARC, 1991. Pp. 246-257.
10. Mackillop WJ, Zhang-Salomons J, Groome PA, et al. Socioeconomic status and cancer survival in Ontario. J Clin Oncol 1997;15:1680-1689. (Pubitemid 27167409)
11. Williams J, Young W. A summary of studies on the quality of health care administrative databases in Canada. In Goel V, Williams JI, Anderson GM, et al. (Eds.), Patterns of health care in Ontario: The ICES Practice Atlas. Ottawa, Canada: Canadian Medical Association, 1996. Pp. 339-345.
12. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383. (Pubitemid 17055592)
13. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
14. Arriagada R, Auperin A, Burdett S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375: 1267-1277.
15. Strauss GM, Herdon MA, Maddaus DM, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 2004;22:abstract 7019.
16. Strauss GM, Herdon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2006;24: abstract 8.
17. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-5051.
18. Booth CM, Mackillop WJ. Translating new medical therapies into societal benefit: the role of population-based outcome studies. JAMA 2008;300:2177-2179.